243 related articles for article (PubMed ID: 26202556)
1. Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base.
Flanagan MR; Rendi MH; Gadi VK; Calhoun KE; Gow KW; Javid SH
Ann Surg Oncol; 2015 Oct; 22(10):3264-72. PubMed ID: 26202556
[TBL] [Abstract][Full Text] [Related]
2. Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.
Nguyen TT; Hoskin TL; Day CN; Habermann EB; Goetz MP; Boughey JC
Ann Surg Oncol; 2017 Oct; 24(10):2989-2998. PubMed ID: 28766214
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen Initiation After Ductal Carcinoma In Situ.
Nichols HB; Bowles EJ; Islam J; Madziwa L; Stürmer T; Tran DT; Buist DS
Oncologist; 2016 Feb; 21(2):134-40. PubMed ID: 26768485
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.
Daly B; Olopade OI; Hou N; Yao K; Winchester DJ; Huo D
JAMA Oncol; 2017 Jul; 3(7):928-935. PubMed ID: 28152150
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
[TBL] [Abstract][Full Text] [Related]
6. Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation.
Punglia RS; Cronin AM; Uno H; Stout NK; Ozanne EM; Greenberg CC; Frank ES; Schrag D
JAMA Oncol; 2017 Jan; 3(1):101-104. PubMed ID: 27442038
[TBL] [Abstract][Full Text] [Related]
7. Patterns of care analysis among women with ductal carcinoma in situ in North Carolina.
Jackson LC; Camacho F; Levine EA; Anderson RT; Stewart JH
Am J Surg; 2008 Feb; 195(2):164-9. PubMed ID: 18096124
[TBL] [Abstract][Full Text] [Related]
8. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.
Zhao H; Hei N; Wu Y; Chan W; Lei X; Cameron C; Chang S; Chavez-MacGregor M; Giordano SH
Cancer; 2017 May; 123(6):940-947. PubMed ID: 27780311
[TBL] [Abstract][Full Text] [Related]
9. Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ.
Hassett MJ; Jiang W; Hughes ME; Edge S; Javid SH; Niland JC; Theriault R; Wong YN; Schrag D; Punglia RS
J Natl Compr Canc Netw; 2018 Apr; 16(4):387-394. PubMed ID: 29632058
[No Abstract] [Full Text] [Related]
10. Prescribing practices of endocrine therapy for ductal carcinoma
Chaudhry AT; Koulis TA; Speers C; Olson RA
Curr Oncol; 2018 Apr; 25(2):133-138. PubMed ID: 29719429
[TBL] [Abstract][Full Text] [Related]
11. Endocrine Therapy Initiation and Medical Oncologist Utilization Among Women Diagnosed with Ductal Carcinoma in Situ.
Anderson C; Meyer AM; Wheeler SB; Zhou L; Reeder-Hayes KE; Nichols HB
Oncologist; 2017 May; 22(5):535-541. PubMed ID: 28408621
[TBL] [Abstract][Full Text] [Related]
12. Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study.
Sprague BL; McLaughlin V; Hampton JM; Newcomb PA; Trentham-Dietz A
Breast Cancer Res Treat; 2013 Aug; 141(1):145-54. PubMed ID: 23979007
[TBL] [Abstract][Full Text] [Related]
13. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L
Cancer; 2006 May; 106(10):2113-8. PubMed ID: 16596655
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.
Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS
Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458
[TBL] [Abstract][Full Text] [Related]
16. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
17. Characterization and treatment of local recurrence following breast conservation for ductal carcinoma in situ.
Greenberg CC; Habel LA; Hughes ME; Nekhlyudov L; Achacoso N; Acton L; Schrag D; Jiang W; Edge S; Weeks JC; Punglia RS
Ann Surg Oncol; 2014 Nov; 21(12):3766-73. PubMed ID: 24859938
[TBL] [Abstract][Full Text] [Related]
18. Does the placement of surgical clips within the excision cavity influence local control for patients treated with breast-conserving surgery and irradiation.
Fein DA; Fowble BL; Hanlon AL; Hoffman JP; Sigurdson ER; Eisenberg BL
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1009-17. PubMed ID: 8600083
[TBL] [Abstract][Full Text] [Related]
19. The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients.
Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
Am J Clin Oncol; 2018 Jul; 41(7):708-715. PubMed ID: 27893470
[TBL] [Abstract][Full Text] [Related]
20. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study.
van Maaren MC; de Munck L; de Bock GH; Jobsen JJ; van Dalen T; Linn SC; Poortmans P; Strobbe LJA; Siesling S
Lancet Oncol; 2016 Aug; 17(8):1158-1170. PubMed ID: 27344114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
